4 Analysts Assess BeiGene: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on BeiGene BGNE in the last three months.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $219.25, along with a high estimate of $345.00 and a low estimate of $161.00. A 9.9% drop is evident in the current average compared to the previous average price target of $243.33.

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of BeiGene's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BeiGene. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BeiGene compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BeiGene's stock. This comparison reveals trends in analysts' expectations over time.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BeiGene's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on BeiGene analyst ratings.

Get to Know BeiGene Better

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene's Financial Performance

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Over the 3 months period, BeiGene showcased positive performance, achieving a revenue growth rate of 66.91% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: BeiGene's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -57.94%, the company may face hurdles in effective cost management.

Return on Equity (ROE): BeiGene's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.07%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): BeiGene's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.49%, the company may face hurdles in achieving optimal financial returns.

Debt Management: With a below-average debt-to-equity ratio of 0.26, BeiGene adopts a prudent financial strategy, indicating a balanced approach to debt management.

How Are Analyst Ratings Determined?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.